VaccinesNews.net

Vaccines Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

EMA’s safety committee, PRAC, has concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. ...


The FDA ( U.S. Food and Drug Administration ) has issued an emergency use authorization ( EUA ) for the third vaccine for the prevention of coronavirus disease 2019 ( COVID-19 ) caused by severe acute ...


EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for COVID-19 Vaccine AstraZeneca to prevent coronavirus disease 2019 ( COVID-19 ) in people from 18 yea ...


The COVID-19 pandemic has caused significant morbidity and mortality throughout the world, as well as major social, educational and economic disruptions. There is an urgent global need for effective ...


All reports of suspected adverse reactions with fatal outcome following COVID-19 vaccination are carefully assessed. The reports have suggested that common adverse reactions to mRNA ( messenger RNA ) ...


During December 14–23, 2020, after administration of 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine ( 1,177,527 doses in females, 648,327 doses in males, and 67,506 doses missing sex ), rep ...


The safety of Comirnaty was evaluated in participants 16 years of age and older in 2 clinical studies that included 21,744 participants that have received at least one dose of Comirnaty. In Study 2, ...


EMA ( European Medicines Agency ) has granted conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 ( COVID-19 ) in peopl ...


EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 ( COVI ...


The U.S. Food and Drug Administration ( FDA ) has issued an emergency use authorization ( EUA ) for the second vaccine for the prevention of coronavirus disease 2019 ( COVID-19 ) caused by severe acut ...


The Pfizer-BioNTech COVID-19 vaccine contains a nucleoside-modified messenger RNA ( modRNA ) encoding the viral spike glycoprotein ( S ) of SARS-CoV-2. Known risks The vaccine has been shown t ...


The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S a ...


The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARSCoV-2 S an ...


The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe COVID-19 are still lacking for this vulnerab ...


There is a large global effort to develop vaccines for protection against COVID-19 and at least 19 vaccine candidates have, as of 31 July 2020, entered clinical trials, including phase 2 and 3 trials. ...